Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6240271 | Journal of Cystic Fibrosis | 2016 | 5 Pages |
Abstract
Premature termination codon read-through drugs offer opportunities for treatment of multiple rare genetic diseases including cystic fibrosis. We here analyzed the read-through efficacy of PTC124 and G418 using human cystic fibrosis intestinal organoids (E60X/4015delATTT, E60X/F508del, G542X/F508del, R1162X/F508del, W1282X/F508del and F508del/F508del). G418-mediated read-through induced only limited CFTR function, but functional restoration of CFTR by PTC124 could not be confirmed. These studies suggest that better read-through agents are needed for robust treatment of nonsense mutations in cystic fibrosis.
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
D.D. Zomer-van Ommen, L.A.W. Vijftigschild, E. Kruisselbrink, A.M. Vonk, J.F. Dekkers, H.M. Janssens, K.M. de Winter-de Groot, C.K. van der Ent, J.M. Beekman,